Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma

Cancer

Volumn 92, Issue 8, 2001, Pages 2158-2163

  Lilenbaum, Rogerio C ^a   Schwartz, Michael A ^a   Seigel, Leonard ^a   Belette, Francisco ^a   Blaustein, Arnold ^a   Wittlin, Frederick N ^a   Davila, Enrique ^a  

^a Mount Sinai Comprehensive Cancer Center   (United States)

Author keywords

Nonsmall cell lung carcinoma (NSCLC); Quality of life; Second line therapy; Weekly docetaxel

Indexed keywords

DEXAMETHASONE; DOCETAXEL;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; LUNG FUNCTION; LUNG NON SMALL CELL CANCER; MALE; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; SURVIVAL ANALYSIS; TAXOIDS;

EID: 0035886546     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20011015)92:8<2158::AID-CNCR1558>3.0.CO;2-2     Document Type: Article

References (10)

1. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
2. Randomized phase II trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens, the TAX 320 Non-Small Cell Lung Cancer Study Group
3. Decetaxel benefits lung cancer symptoms and quality of life in a randomized phase III study of non-small cell lung cancer patients previously treated with platinum-based chemotherapy
4. Quality of life assessment in a randomized study of taxotere versus best supportive care in nonsmall cell lung cancer patients previously treated with platinum-based chemotherapy
5. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer
6. Weekly docetaxel as second line therapy of advanced non-small cell lung cancer (NSCLC): A preliminary feasibility report
7. Early phase II of docetaxel in second line of advanced non-small cell lung cancer (NSCLC): Preliminary results
8. Docetaxel administered on a weekly basis for metastatic breast cancer
9. Phase II study of weekly docetaxel (taxotere) in hormone refractory metastatic prostate cancer
10. Weekly docetaxel in the treatment of elderly patients with advanced non-small cell lung carcinoma